Efficacy of topotecan plus vincristine and doxorubicin in children with recurrent/refractory rhabdomyosarcoma

[1]  D. Rodeberg,et al.  Randomized phase III trial comparing vincristine, actinomycin, cyclophosphamide (VAC) with VAC/V topotecan/cyclophosphamide (TC) for intermediate risk rhabdomyosarcoma (IRRMS). D9803, COG study , 2007 .

[2]  James R. Anderson,et al.  Pooled analysis of phase II window studies in children with contemporary high-risk metastatic rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  W. Meyer,et al.  Efficacy of topotecan and cyclophosphamide given in a phase II window trial in children with newly diagnosed metastatic rhabdomyosarcoma: a Children's Oncology Group study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  R. Pollock,et al.  Soft Tissue Sarcomas , 2001, CA: a cancer journal for clinicians.

[5]  P. Houghton,et al.  Topoisomerase I interactive drugs in children with cancer , 2004, Investigational New Drugs.

[6]  P. Houghton,et al.  Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors , 2004, Cancer Chemotherapy and Pharmacology.

[7]  G. Severi,et al.  A phase II study of topotecan with vincristine and doxorubicin in children with recurrent/refractory neuroblastoma , 2003, Cancer.

[8]  M. Bernstein,et al.  Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  J. Meza,et al.  Up-front window trial of topotecan in previously untreated children and adolescents with metastatic rhabdomyosarcoma: an intergroup rhabdomyosarcoma study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  James R. Anderson,et al.  Benefit of intensified therapy for patients with local or regional embryonal rhabdomyosarcoma: results from the Intergroup Rhabdomyosarcoma Study IV. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  P. Houghton,et al.  Synergy of topotecan in combination with vincristine for treatment of pediatric solid tumor xenografts. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[12]  P. Houghton,et al.  Animal models for studying the action of topoisomerase I targeted drugs. , 1998, Biochimica et biophysica acta.

[13]  M. Bernstein,et al.  Topotecan in Pediatric Patients With Recurrent and Progressive Solid Tumors: A Pediatric Oncology Group Phase II Study , 1998, Journal of pediatric hematology/oncology.

[14]  R. Larsson,et al.  Synergistic interactions of combinations of topotecan with standard drugs in primary cultures of human tumor cells from patients , 1998, European Journal of Clinical Pharmacology.

[15]  J. Verweij,et al.  Review of phase I clinical studies with topotecan. , 1997, Seminars in oncology.

[16]  S. Kaufmann,et al.  Topotecan in combination chemotherapy. , 1997, Seminars in oncology.

[17]  J. Ross,et al.  Epidemiology of acute leukemia in children and adults. , 1997, Seminars in oncology.

[18]  J. Kurtzberg,et al.  Phase I Trial and Pharmacokinetic (PK) and Pharmacodynamics (PD) Study of Topotecan Using a Five‐Day Course in Children with Refractory Solid Tumors: A Pediatric Oncology Group Study , 1996, Journal of pediatric hematology/oncology.

[19]  E. Gehan,et al.  The Third Intergroup Rhabdomyosarcoma Study. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  S. Chatterjee,et al.  Schedule-dependent cytotoxicity of topotecan alone and in combination chemotherapy regimens. , 1994, Oncology research.

[21]  R. Kim,et al.  Experimental studies on biochemical modulation targeting topoisomerase I and II in human tumor xenografts in nude mice , 1992, International journal of cancer.

[22]  S. George,et al.  Phase II testing of melphalan in children with newly diagnosed rhabdomyosarcoma: a model for anticancer drug development. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  B Sundell,et al.  Soft-tissue sarcomas. , 1979, British medical journal.